Neurotrophic Keratitis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Oyster Point Pharma, Recordati Rare Diseases, MimeTech,

Posted on
by

Neurotrophic Keratitis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Oyster Point Pharma, Recordati Rare Diseases, MimeTech,
“Neurotrophic Keratitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurotrophic Keratitis, historical and forecasted epidemiology as well as the Neurotrophic Keratitis market trends in the 7MM.

DelveInsight’s “Neurotrophic Keratitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurotrophic Keratitis, historical and forecasted epidemiology as well as the Neurotrophic Keratitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Neurotrophic Keratitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratitis Market Forecast

 

Some of the key facts of the Neurotrophic Keratitis Market Report: 

  • The Neurotrophic Keratitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In the 7MM, there were 137,500 prevalent instances of NK in total in 2021. This increase of NK cases in the 7MM is anticipated to occur between 2022 and 2032
  • The United States has the most common cases of NK out of all the seven main markets. In the US, 65,000 common instances of NK were reported in 2021
  • The highest diagnosed prevalence of NK was found in the UK, followed by Germany, among the EU4 and the UK
  • In the US in 2021, there were around 50,300 cases of NK that were really identified
  • In 2021, there were 101,500 diagnosed cases of NK in the 7MM as a whole
  • In the US, the greatest documented prevalence and diagnosis rate of NK in the 7MM population occurred in 2021
  • Key Neurotrophic Keratitis Companies: Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotechnology Inc., Dompé Farmaceutici S.p.A, Syneos Health, ReGenTree, LLC, and others
  • Key Neurotrophic Keratitis Therapies: OC-01, REC 0559, CSB-001, RGN-259, BRM424, cenegermin-bkbj, Udonitrectag, RGN-259, and others 
  • The Neurotrophic Keratitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratitis pipeline products will significantly revolutionize the Neurotrophic Keratitis market dynamics. 

 

Get a Free sample for the Neurotrophic Keratitis Market Report 

https://www.delveinsight.com/report-store/neurotrophic-keratitis-market

 

Neurotrophic Keratitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Neurotrophic Keratitis Epidemiology Segmentation:

The Neurotrophic Keratitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Neurotrophic Keratitis
  • Prevalent Cases of Neurotrophic Keratitis by severity
  • Gender-specific Prevalence of Neurotrophic Keratitis
  • Diagnosed Cases of Episodic and Chronic Neurotrophic Keratitis

 

Download the report to understand which factors are driving Neurotrophic Keratitis epidemiology trends @ Neurotrophic Keratitis Epidemiology Forecast

 

Neurotrophic Keratitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurotrophic Keratitis market or expected to get launched during the study period. The analysis covers Neurotrophic Keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neurotrophic Keratitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Neurotrophic Keratitis Therapies and Key Companies

  • OC-01: Oyster Point Pharma
  • REC 0559: Recordati Rare Diseases/MimeTech
  • CSB-001: Claris Biotherapeutics
  • RGN-259: ReGenTree
  • BRM424: BRIM Biotechnology Inc.
  • cenegermin-bkbj: Dompé Farmaceutici S.p.A
  • Udonitrectag: Syneos Health
  • RGN-259: ReGenTree, LLC

 

Discover more about therapies set to grab major Neurotrophic Keratitis market share @ Neurotrophic Keratitis Treatment Market

 

Neurotrophic Keratitis Market Strengths

  • Increasing prevalence of other conditions causes neurotrophic keratitis, thereby increasing NK population.
  • The development of novel molecules potentially targets epithelial healing and corneal innervation.
  • Advances in biotechnology, laser and robotic treatment also aid in the treatment of Neurotrophic Keratitis.

 

Neurotrophic Keratitis Market Opportunities

  • The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factors for the treatment of neurotrophic keratitis during the forecast period.
  • Researchers are increasing their investments to develop and discover drugs that could potentially treat rare eye disease

 

Scope of the Neurotrophic Keratitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Neurotrophic Keratitis Companies: Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotechnology Inc., Dompé Farmaceutici S.p.A, Syneos Health, ReGenTree, LLC, and others
  • Key Neurotrophic Keratitis Therapies: OC-01, REC 0559, CSB-001, RGN-259, BRM424, cenegermin-bkbj, Udonitrectag, RGN-259, and others
  • Neurotrophic Keratitis Therapeutic Assessment: Neurotrophic Keratitis current marketed and Neurotrophic Keratitis emerging therapies
  • Neurotrophic Keratitis Market Dynamics: Neurotrophic Keratitis market drivers and Neurotrophic Keratitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Neurotrophic Keratitis Unmet Needs, KOL’s views, Analyst’s views, Neurotrophic Keratitis Market Access and Reimbursement 

 

To know more about Neurotrophic Keratitis companies working in the treatment market, visit @ Neurotrophic Keratitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Neurotrophic Keratitis Market Report Introduction

2. Executive Summary for Neurotrophic Keratitis

3. SWOT analysis of Neurotrophic Keratitis

4. Neurotrophic Keratitis Patient Share (%) Overview at a Glance

5. Neurotrophic Keratitis Market Overview at a Glance

6. Neurotrophic Keratitis Disease Background and Overview

7. Neurotrophic Keratitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Neurotrophic Keratitis 

9. Neurotrophic Keratitis Current Treatment and Medical Practices

10. Neurotrophic Keratitis Unmet Needs

11. Neurotrophic Keratitis Emerging Therapies

12. Neurotrophic Keratitis Market Outlook

13. Country-Wise Neurotrophic Keratitis Market Analysis (2019–2032)

14. Neurotrophic Keratitis Market Access and Reimbursement of Therapies

15. Neurotrophic Keratitis Market Drivers

16. Neurotrophic Keratitis Market Barriers

17.  Neurotrophic Keratitis Appendix

18. Neurotrophic Keratitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services